In patients with AD, cerebral glucose hypometabolism, measured by fluorodeoxyglucose-18-PET, correlates with tau deposits measured by tau PET, and glucose hypometabolism and the regional distribution of tau deposits correlate well with symptom severity [6,7]. This evidence concerns the gene MAPT and Alzheimer disease.